{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-019999","form_type":"8-K","ticker":"TWST","cik":"0001581280","company_name":"Twist Bioscience Corp","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.066138+00:00","generated_at":"2026-06-03T00:29:19.603733+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Twist Bioscience reports record Q2 revenue $75.3M (+25% YoY), raises FY2024 guidance","bullets":["Record revenue $75.3M (+25% YoY); orders $93.2M (+45% YoY).","Net loss $45.5M ($0.79/sh) vs $59.2M ($1.04) YoY; adjusted EBITDA -$26.8M.","Gross margin improved to 41% from 31%; FY2024 revenue guidance raised to $300-304M, gross margin 41.5-42.0%.","Cash burn improved: net cash from ops -$42.4M H1FY24 vs -$98.4M; cash $293.3M.","NGS revenue $40.8M (+41% YoY), SynBio $29.8M (+23%), Biopharma $4.7M (-33%)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-019999","json":"https://secwatch.observer/filing/0001628280-24-019999.json","markdown":"https://secwatch.observer/filing/0001628280-24-019999.md","text":"https://secwatch.observer/filing/0001628280-24-019999.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1581280/000162828024019999/0001628280-24-019999-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1581280/000162828024019999/twist-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:29:19.603733+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c175a1c546b8b78014a37c158d0239a8cf4a6fe1","claim":"Twist Bioscience Corp reported fiscal year 2024 results: revenue $300M to $304M. Guidance raised.","evidence_excerpt":"— Increased FY 2024 revenue guidance to a range of $300M to $304M; Increased FY 2024 gross margin guidance to a range of 41.5 to 42.0% —","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1581280/000162828024019999/0001628280-24-019999-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2024"},{"label":"Revenue","value":"$300M to $304M"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}]},{"claim_id":"fc462f1c5e1adcab94cda444814c1e4bda35b3a0","claim":"Twist Bioscience Corp reported fiscal second quarter ended March 31, 2024 results: revenue $75.3 million, net income -$45.5 million, EPS -$0.79.","evidence_excerpt":"FISCAL 2024 SECOND QUARTER FINANCIAL RESULTS • Orders: Total orders received for the second quarter of fiscal 2024 increased to $93.2 million compared to $64.2 million for the same period of fiscal 2023 . • Revenue: Total revenues for the second quarter of fiscal 2024 increased to $75.3 million compared to $60.2 million for the same period of fiscal 2023 . ◦ SynBio revenue increased to $29.8 million for the second quarter of fiscal 2024 compared to $24.2 million for the same period of fiscal 2023. ◦ NGS revenue increased to $40.8 million for the second quarter of fiscal 2024 compared to $29.0 million for the same period of fiscal 2023. ◦ Biopharma revenue was $4.7 million for the second quarter of fiscal 2024 compared to $7.0 million in the same period of fiscal 2023. • Cost of Revenues: Cost of revenues for the second quarter of fiscal 2024 was $44.4 million compared to $41.7 million for the same period of fiscal 2023 . • Gross Margin: Gross margin for the second quarter of fiscal 202","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1581280/000162828024019999/0001628280-24-019999-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal second quarter ended March 31, 2024"},{"label":"Revenue","value":"$75.3 million"},{"label":"Net income","value":"-$45.5 million"},{"label":"EPS","value":"-$0.79"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}